Create Account | Sign In: Author or Forum

Search Symptoms

Category: Dermatology | Family Medicine | Internal Medicine | Nursing | Ophthalmology | Pharmacy | Surgery | Journal

Back to Journal Articles

Study Compares Onset of Action of Two Types of Botulinum Toxin

Last Updated: December 26, 2011.

The onset action of two botulinum neuromodulators demonstrates improvements in the appearance of lateral orbital rhytids (crow's feet), although abobotulinumtoxinA shows greater improvement than onabotulinumtoxinA, according to a study published online Dec. 19 in the Archives of Facial Plastic Surgery.

MONDAY, Dec. 26 (HealthDay News) -- Two botulinum neuromodulators demonstrate early improvements in the appearance of lateral orbital rhytids (crow's feet), but abobotulinumtoxinA results in greater improvement than onabotulinumtoxinA, according to a study published online Dec. 19 in the Archives of Facial Plastic Surgery.

Kenneth C.Y. Yu, M.D., from the University of California San Francisco, and colleagues enrolled 90 patients (77 women and 13 men) who had moderate to severe lateral orbital rhytids. In the split-face, double-blind study, the researchers injected onabotulinumtoxinA (10 U) on one side of the face and abobotulinumtoxinA (30 U) on the other side of the face. Participants were evaluated live with a validated five-point photographic scale before treatment and on days two, four, and six after treatment.

When evaluated independently by investigator and participant, the researchers found that abobotulinumtoxinA and onabotulinumtoxinA demonstrated statistically significant change from baseline at day two in the treatment of lateral orbital rhytids at maximal contraction and rest. AbobotulinumtoxinA's greater improvement achieved statistical significance by day four, remaining superior at day six. No adverse effects or complications occurred with either product during the study.

"Both abobotulinumtoxinA and onabotulinumtoxinA achieved statistically significant onset of action at day two. This improvement was seen in all end points, with abobotulinumtoxinA demonstrating a trend toward greater improvement than onabotulinumtoxinA at day two and a statistically significant greater improvement at days four and six when looking at maximal contraction," the authors write.

Abstract
Full Text


Previous: Extended Nevirapine Reduces Breastfeeding HIV Transmission Next: Coronary MRI Good Alternative to SPECT for CHD Diagnosis

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: